Abstract In 2014, our research network was involved in the evaluation of favipiravir, an anti-Influenza polymerase inhibitor, against Ebola virus. In this review we discuss how mathematical modelling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a non-human […]
Click here to view original web page at www.ncbi.nlm.nih.gov
